Bulletin
Investor Alert

London Markets Open in:

Edesa Biotech Inc.

NAS: EDSA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Sep 26, 2023, 4:01 p.m.

/zigman2/quotes/200172674/composite

$

0.88

Change

+0.07 +7.98%

Volume

Volume 3

Quotes are delayed by 20 min

/zigman2/quotes/200172674/composite

Previous close

$ 0.85

$ 0.82

Change

-0.04 -4.23%

Day low

Day high

$0.81

$0.86

Open

52 week low

52 week high

$0.76

$2.81

Open

Company Description

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01...

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases. Its clinical studies include EB05 for Acute Respiratory Distress Syndrome (ARDS), EB07 for systemic sclerosis (SSc), EB01 for chronic Allergic Contact Dermatitis (ACD), EB02 for hemorrhoids, and EB06 for vitiligo. The company was founded by Pardeep Nijhawan on June 12, 2007 and is headquartered in Markham, Canada.

Valuation

Price to Book Ratio

1.63

Enterprise Value to EBITDA

-0.62

Total Debt to Enterprise Value

0.00

Efficiency

Income Per Employee

-1,096,808.00

Liquidity

Current Ratio

4.25

Quick Ratio

4.25

Cash Ratio

3.31

Profitability

Return on Assets

-134.16

Return on Equity

-156.34

Return on Total Capital

-162.80

Return on Invested Capital

-156.20

Capital Structure

Total Debt to Total Equity

0.20

Total Debt to Total Capital

0.20

Total Debt to Total Assets

0.16

Officers and Executives

Name Age Officer Since Title
Dr. Pardeep Nijhawan 51 2015 Chief Executive Officer, Secretary & Director
Dr. Michael Brooks 41 2015 Vice President- Corporate Development & Strategy
Mr. Stephen L. Lemieux 46 2023 Chief Financial Officer
Dr. Blair Gordon - 2016 Vice President-Research & Development
Mr. Rajan Puri - 2021 Senior Vice President-Manufacturing

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/edsa

MarketWatch News on EDSA

  1. Stellar Biotechnologies stock price target cut to $7 from $17 at Maxim Group

    7:50 a.m. Aug. 1, 2016

    - Tomi Kilgore

  2. Stellar Biotechnologies Gets a Positive Sign

    1:03 a.m. Feb. 26, 2016

    - Barron's Online

/news/nonmarketwatch/company/us/edsa

Other News on EDSA

  1. 10-Q: EDESA BIOTECH, INC.

    4:49 p.m. May 11, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-Q: EDESA BIOTECH, INC.

    5:21 p.m. Feb. 10, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  3. 10-K: EDESA BIOTECH, INC.

    5:16 p.m. Dec. 16, 2022

    - Edgar Online - (EDG = 10Q, 10K)

At a Glance

Edesa Biotech, Inc.

100 Spy Court

Markham, Ontario L3R 5H6

Phone

1 2898009600

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

09/2023

Revenue

N/A

Net Income

$-17.55M

Employees

16.00

/news/pressrelease/company/us/edsa

Press Releases on EDSA

  1. Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

    4:30 p.m. May 11, 2023

    - ACCESSWIRE

  2. Edesa Biotech to Participate in Swiss Biotech Day

    8:30 a.m. April 20, 2023

    - ACCESSWIRE

  3. Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

    10:00 a.m. Feb. 10, 2023

    - ACCESSWIRE

  4. Edesa Biotech Reports Fiscal Year 2022 Results

    10:01 a.m. Dec. 16, 2022

    - ACCESSWIRE

Link to MarketWatch's Slice.